{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:20:17Z","timestamp":1787901617632,"version":"build-2784847793"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japan Institute for Health Security"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peritoneal metastasis (PM) is the most common and clinically devastating mode of spread in Gastric Cancer. Despite advances in systemic therapy, outcomes for gastric cancer with peritoneal metastasis (GCPM) remain poor, largely because the distinctive biology of PM, including sparse vascularization and the peritoneal\u2013plasma barrier, restricts drug delivery and promotes therapeutic resistance. To overcome these limitations, locoregional approaches such as cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS\u2009+\u2009HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) have been introduced, but their broader use remains limited by invasiveness, patient selection challenges, and variable survival benefits. In this setting, catheter-based normothermic intraperitoneal chemotherapy (CBIP) has emerged as a practical and scalable strategy, particularly in East Asia. By enabling repeated intraperitoneal administration through an implanted port, CBIP provides sustained regional drug exposure with minimal procedural burden and can be readily combined with systemic therapy. Among available agents, Paclitaxel and Docetaxel are especially suitable because of their prolonged peritoneal retention and low systemic absorption. Accordingly, taxane-based CBIP represents a biologically rational and clinically feasible platform for GCPM. In this review, we summarize its pharmacologic basis, clinical evidence, and future innovations in drug formulation and delivery that may further improve outcomes in this highly challenging disease.<\/jats:p>","DOI":"10.1007\/s10120-026-01767-2","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:22:26Z","timestamp":1781742146000},"page":"904-919","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside\u2014a narrative review"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-7130","authenticated-orcid":false,"given":"Joji","family":"Kitayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"1767_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. May-Jun 2024;74(3):229-263.","DOI":"10.3322\/caac.21834"},{"issue":"1","key":"1767_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1767_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622\u20138.","journal-title":"Int J Cancer"},{"issue":"32","key":"1767_CR4","doi-asserted-by":"publisher","first-page":"52307","DOI":"10.18632\/oncotarget.10740","volume":"7","author":"M Riihimaki","year":"2016","unstructured":"Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307\u201316.","journal-title":"Oncotarget"},{"issue":"4","key":"1767_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","volume":"24","author":"WJ Koemans","year":"2021","unstructured":"Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24(4):800\u20139.","journal-title":"Gastric Cancer"},{"issue":"1 Pt B","key":"1767_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.amjsurg.2022.01.024","volume":"224","author":"J Sirody","year":"2022","unstructured":"Sirody J, Kaji AH, Hari DM, Chen KT. Patterns of gastric cancer metastasis in the United States. Am J Surg. 2022;224(1 Pt B):445\u20138.","journal-title":"Am J Surg"},{"issue":"5","key":"1767_CR7","first-page":"820","volume":"110","author":"Y Maehara","year":"1991","unstructured":"Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haraguchi M, et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery. 1991;110(5):820\u20133.","journal-title":"Surgery"},{"issue":"6","key":"1767_CR8","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ijc.34780","volume":"154","author":"A Rijken","year":"2024","unstructured":"Rijken A, Pape M, Simkens GA, de Hingh I, Luyer MDP, van Sandick JW, et al. Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival. Int J Cancer. 2024;154(6):992\u20131002.","journal-title":"Int J Cancer"},{"issue":"33","key":"1767_CR9","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387\u201393.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1767_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. investigators Ct. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389\u201396.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1767_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"1767_CR12","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2025 (7th edition). Gastric Cancer. 2026;29(2):271\u2013299.","DOI":"10.1007\/s10120-025-01698-4"},{"issue":"3","key":"1767_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1515\/pp-2016-0015","volume":"1","author":"W Solass","year":"2016","unstructured":"Solass W, Horvath P, Struller F, Konigsrainer I, Beckert S, Konigsrainer A, et al. Functional vascular anatomy of the peritoneum in health and disease. Pleura Peritoneum. 2016;1(3):145\u201358.","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"1767_CR14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1186\/s12885-020-07477-x","volume":"20","author":"D Fujimori","year":"2020","unstructured":"Fujimori D, Kinoshita J, Yamaguchi T, Nakamura Y, Gunjigake K, Ohama T, et al. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer. BMC Cancer. 2020;20(1):1014.","journal-title":"BMC Cancer"},{"key":"1767_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363.","journal-title":"Cancer Treat Res"},{"issue":"4","key":"1767_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.5230\/jgc.2025.25.e46","volume":"25","author":"H Kim","year":"2025","unstructured":"Kim H, Kwon M, Lee SK, Son SM, Lee OJ, Man Yoon S, et al. Distinct immunosuppressive tumor microenvironment in gastric cancer with peritoneal metastasis. J Gastric Cancer. 2025;25(4):605\u201320.","journal-title":"J Gastric Cancer"},{"key":"1767_CR17","doi-asserted-by":"crossref","unstructured":"Cortes-Guiral D, Hubner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):91.","DOI":"10.1038\/s41572-021-00326-6"},{"key":"1767_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864647","volume":"12","author":"A Prabhu","year":"2022","unstructured":"Prabhu A, Mishra D, Brandl A, Yonemura Y. Gastric cancer with peritoneal metastasis-a comprehensive review of current intraperitoneal treatment modalities. Front Oncol. 2022;12:864647.","journal-title":"Front Oncol"},{"key":"1767_CR19","doi-asserted-by":"crossref","unstructured":"Sammartino P, De Manzoni G, Marano L, Marrelli D, Biacchi D, Sommariva A, Scaringi S, Federici O, Guaglio M, Angrisani M, Cardi M, Fassari A, Casella F, Graziosi L, Roviello F. Gastric Cancer (GC) with Peritoneal Metastases (PMs): An Overview of Italian PSM Oncoteam Evidence and Study Purposes. Cancers (Basel). 2023;15(12):3137.","DOI":"10.3390\/cancers15123137"},{"issue":"3","key":"1767_CR20","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/curroncol31030109","volume":"31","author":"M Acs","year":"2024","unstructured":"Acs M, Piso P, Glockzin G. Peritoneal metastatic gastric cancer: local treatment options and recommendations. Curr Oncol. 2024;31(3):1445\u201359.","journal-title":"Curr Oncol"},{"issue":"2","key":"1767_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"key":"1767_CR22","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Shitara K, Ajani JA, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, McCraith S, Hu N, Lei M, Zhang J, Moehler M. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Ann Oncol. 2026.","DOI":"10.1016\/j.annonc.2026.02.003"},{"issue":"3","key":"1767_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00000421-198806000-00013","volume":"11","author":"JR Oleson","year":"1988","unstructured":"Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA Jr., et al. Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol. 1988;11(3):368\u201380.","journal-title":"Am J Clin Oncol"},{"key":"1767_CR24","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh I, van der Velden J, Arts HJ, Massuger L, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u2013240.","DOI":"10.1056\/NEJMoa1708618"},{"issue":"8","key":"1767_CR25","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/bjc.2014.419","volume":"111","author":"R Mirnezami","year":"2014","unstructured":"Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111(8):1500\u20138.","journal-title":"Br J Cancer"},{"key":"1767_CR26","doi-asserted-by":"crossref","unstructured":"Graf W, Ghanipour L, Birgisson H, Cashin PH. Cytoreductive Surgery and Hyperthermic intraperitoneal chemotherapy for peritoneal metastases from colorectal cancer-an overview of current status and future perspectives. Cancers (Basel). 2024;16(2):284.","DOI":"10.3390\/cancers16020284"},{"issue":"8","key":"1767_CR27","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1245\/s10434-025-17518-z","volume":"32","author":"M Tonello","year":"2025","unstructured":"Tonello M, Cenzi C, Pizzolato E, Martini M, Pilati P, Sommariva A. National guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal malignancies: A worldwide systematic review and recommendations of strength analysis. Ann Surg Oncol. 2025;32(8):5795\u2013806.","journal-title":"Ann Surg Oncol"},{"key":"1767_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2025.116235","volume":"242","author":"Z Pelc","year":"2025","unstructured":"Pelc Z, Sedlak K, Endo Y, Van Sandick J, Gisbertz S, Pera M, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal metastasis - joint analysis of European GASTRODATA and American national cancer database. Am J Surg. 2025;242:116235.","journal-title":"Am J Surg"},{"key":"1767_CR29","doi-asserted-by":"crossref","unstructured":"Tops-Welten MW, Galanos LJK, Creemers GJ, Luyer MDP, De Hingh I, van Hellemond IEG. Gastrointestinal CancerEmerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review. Oncologist. 2025;30(9):oyaf219.","DOI":"10.1093\/oncolo\/oyaf219"},{"issue":"2","key":"1767_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, Gockel I, Rau HG, Seeliger H, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42(2):146\u201356.","journal-title":"J Clin Oncol"},{"key":"1767_CR31","unstructured":"Quik JS. PERISCOPE II Trial: Randomized study finds no OS advantage for gastrectomy plus CRS\/HIPEC versus systemic therapy. ESMO, Proceedings. 2025."},{"issue":"2","key":"1767_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","volume":"20","author":"G Nadiradze","year":"2016","unstructured":"Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367\u201373.","journal-title":"J Gastrointest Surg"},{"key":"1767_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.addr.2020.10.015","volume":"160","author":"M Rahimi-Gorji","year":"2020","unstructured":"Rahimi-Gorji M, Van de Sande L, Debbaut C, Ghorbaniasl G, Braet H, Cosyns S, et al. Intraperitoneal aerosolized drug delivery: technology, recent developments, and future outlook. Adv Drug Deliv Rev. 2020;160:105\u201314.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"1767_CR34","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, Hubner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368\u201377.","journal-title":"Lancet Oncol"},{"key":"1767_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919846402","volume":"11","author":"F Struller","year":"2019","unstructured":"Struller F, Horvath P, Solass W, Weinreich FJ, Strumberg D, Kokkalis MK, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1767_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47(1):123\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1767_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10585-020-10023-5","volume":"37","author":"SB Ellebaek","year":"2020","unstructured":"Ellebaek SB, Graversen M, Detlefsen S, Lundell L, Fristrup CW, Pfeiffer P, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study. Clin Exp Metastasis. 2020;37(2):325\u201332.","journal-title":"Clin Exp Metastasis"},{"key":"1767_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goaf040","volume":"13","author":"R Chen","year":"2025","unstructured":"Chen R, Yang Z, Li R, Yang Y, Zheng J, Wang J, et al. Pressurized intraperitoneal aerosol chemotherapy in advanced gastric cancer with peritoneal metastases: a comprehensive meta-analysis of feasibility, efficacy, and safety. Gastroenterol Rep. 2025;13:goaf040.","journal-title":"Gastroenterol Rep"},{"issue":"4","key":"1767_CR39","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1767_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343.","journal-title":"N Engl J Med"},{"issue":"4","key":"1767_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jso.21324","volume":"100","author":"Y Yonemura","year":"2009","unstructured":"Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol. 2009;100(4):311\u20136.","journal-title":"J Surg Oncol"},{"issue":"4","key":"1767_CR42","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1245\/s10434-013-3443-2","volume":"21","author":"E Canbay","year":"2014","unstructured":"Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147\u201352.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1767_CR43","doi-asserted-by":"publisher","first-page":"F999","DOI":"10.1152\/ajprenal.00012.2016","volume":"311","author":"J Perl","year":"2016","unstructured":"Perl J, Bargman JM. Peritoneal dialysis: from bench to bedside and bedside to bench. Am J Physiol Renal Physiol. 2016;311(5):F999\u20131004.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"1767_CR44","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1\u201311.","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"1767_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277\u201383.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1767_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1515\/pp-2017-0010","volume":"2","author":"E de Bree","year":"2017","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2(2):47\u201362.","journal-title":"Pleura Peritoneum"},{"issue":"7","key":"1767_CR47","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40265-025-02195-9","volume":"85","author":"PCS Rietveld","year":"2025","unstructured":"Rietveld PCS, Guchelaar NAD, Sassen SDT, Koch BCP, Mathijssen RHJ, Koolen SLW. A clinical pharmacological perspective on intraperitoneal chemotherapy. Drugs. 2025;85(7):931\u201343.","journal-title":"Drugs"},{"issue":"3","key":"1767_CR48","doi-asserted-by":"publisher","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"MF Flessner","year":"2005","unstructured":"Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288(3):F433-442.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"1767_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","volume":"7","author":"WP Ceelen","year":"2010","unstructured":"Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010;7(2):108\u201315.","journal-title":"Nat Rev Clin Oncol"},{"key":"1767_CR50","doi-asserted-by":"crossref","unstructured":"Kamiya K, Hatayama N, Tawada M, Asai A, Yamauchi M, Kinashi H, Kunoki S, Yamaguchi M, Mizuno M, Suzuki Y, Banshodani M, Ishimoto T, Naito M, Kawanishi H, Ito Y. Role of endothelial hyaluronan in peritoneal membrane transport and disease conditions during peritoneal dialysis. Sci Rep. 2024;14(1):7412.","DOI":"10.1038\/s41598-024-58148-x"},{"issue":"1\u20132","key":"1767_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","volume":"235","author":"AK Singla","year":"2002","unstructured":"Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235(1\u20132):179\u201392.","journal-title":"Int J Pharm"},{"issue":"1","key":"1767_CR52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1586\/14737140.1.1.142","volume":"1","author":"M Markman","year":"2001","unstructured":"Markman M. Intraperitoneal chemotherapy in the management of malignant disease. Expert Rev Anticancer Ther. 2001;1(1):142\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl 1","key":"1767_CR53","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.21037\/jgo-2020-03","volume":"12","author":"PH Sugarbaker","year":"2021","unstructured":"Sugarbaker PH. Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects. J Gastrointest Oncol. 2021;12(Suppl 1):S231\u20139.","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"1767_CR54","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","volume":"83","author":"NAD Guchelaar","year":"2023","unstructured":"Guchelaar NAD, Noordman BJ, Koolen SLW, Mostert B, Madsen EVE, Burger JWA, et al. Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies. Drugs. 2023;83(2):159\u201380.","journal-title":"Drugs"},{"issue":"4","key":"1767_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1023\/A:1015175108183","volume":"19","author":"JK Jackson","year":"2002","unstructured":"Jackson JK, Skinner KC, Burgess L, Sun T, Hunter WL, Burt HM. Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. Pharm Res. 2002;19(4):411\u20137.","journal-title":"Pharm Res"},{"issue":"12","key":"1767_CR56","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1167\/iovs.08-1694","volume":"49","author":"HK Choung","year":"2008","unstructured":"Choung HK, Jin SE, Lee MJ, Kim CK, Hwang JM. Slow-releasing paclitaxel in polytetrafluoroethylene\/polylactide-co-glycolide laminate delays adjustment after strabismus surgery in rabbit model. Invest Ophthalmol Vis Sci. 2008;49(12):5340\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1767_CR57","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0090-9556(25)06648-6","volume":"23","author":"F Innocenti","year":"1995","unstructured":"Innocenti F, Danesi R, Di Paolo A, Agen C, Nardini D, Bocci G, et al. Plasma and tissue disposition of paclitaxel (Taxol) after intraperitoneal administration in mice. Drug Metab Dispos. 1995;23(7):713\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1767_CR58","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1055-3207(03)00038-3","volume":"12","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin N Am. 2003;12(3):825\u201333.","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"1767_CR59","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jss.2008.06.049","volume":"155","author":"D Soma","year":"2009","unstructured":"Soma D, Kitayama J, Ishigami H, Kaisaki S, Nagawa H. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. J Surg Res. 2009;155(1):142\u20136.","journal-title":"J Surg Res"},{"issue":"9","key":"1767_CR60","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-06-1941","volume":"13","author":"AH Kyle","year":"2007","unstructured":"Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res. 2007;13(9):2804\u201310.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1767_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1593\/neo.03205","volume":"6","author":"AW El-Kareh","year":"2004","unstructured":"El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004;6(2):117\u201327.","journal-title":"Neoplasia"},{"issue":"8","key":"1767_CR62","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ejso.2011.04.007","volume":"37","author":"PH Sugarbaker","year":"2011","unstructured":"Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol. 2011;37(8):719\u201326.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"1767_CR63","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.21873\/anticanres.11008","volume":"36","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, Forster E, Osma A, et al. Evaluating the effect of Micropump(c) position, internal pressure and doxorubicin dosage on efficacy of pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in an ex vivo model. Anticancer Res. 2016;36(9):4595\u2013600.","journal-title":"Anticancer Res"},{"issue":"11","key":"1767_CR64","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJ, Osma A, Kabakci B, Diaz-Carballo D, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142(11):2275\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1767_CR65","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, Murdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"1767_CR66","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/j.1349-7006.2009.01265.x","volume":"100","author":"D Soma","year":"2009","unstructured":"Soma D, Kitayama J, Konno T, Ishihara K, Yamada J, Kamei T, et al. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. Cancer Sci. 2009;100(10):1979\u201385.","journal-title":"Cancer Sci"},{"issue":"1","key":"1767_CR67","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1349-7006.2010.01747.x","volume":"102","author":"T Kamei","year":"2011","unstructured":"Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 2011;102(1):200\u20135.","journal-title":"Cancer Sci"},{"issue":"11","key":"1767_CR68","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.1984.2.11.1277","volume":"2","author":"CE Pfeifle","year":"1984","unstructured":"Pfeifle CE, Howell SB, Markman M, Lucas WE. Totally implantable system for peritoneal access. J Clin Oncol. 1984;2(11):1277\u201380.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1767_CR69","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00280-014-2393-0","volume":"73","author":"J Kitayama","year":"2014","unstructured":"Kitayama J, Emoto S, Yamaguchi H, Ishigami H, Watanabe T. Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels. Cancer Chemother Pharmacol. 2014;73(3):605\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1767_CR70","doi-asserted-by":"crossref","unstructured":"Tamura K, Kimura N, Ohzawa H, Miyato H, Sata N, Koyanagi T, Saga Y, Takei Y, Fujiwara H, Nagai R, Kitayama J, Aizawa K. Optimizing timing of intraperitoneal chemotherapy to enhance intravenous carboplatin concentration. Cancers (Basel). 2024;16(16):2841.","DOI":"10.3390\/cancers16162841"},{"issue":"5","key":"1767_CR71","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000209277","volume":"76","author":"H Ishigami","year":"2009","unstructured":"Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76(5):311\u20134.","journal-title":"Oncology"},{"issue":"1","key":"1767_CR72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67\u201370.","journal-title":"Ann Oncol"},{"issue":"18","key":"1767_CR73","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.28204","volume":"119","author":"H Yamaguchi","year":"2013","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119(18):3354\u20138.","journal-title":"Cancer"},{"issue":"19","key":"1767_CR74","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018;36(19):1922\u20139.","journal-title":"J Clin Oncol"},{"issue":"15(suppl)","key":"1767_CR75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.4040","volume":"34","author":"Y Fujiwara","year":"2016","unstructured":"Fujiwara Y, Ishigami H, Miwa H, Tanaka T, Kodera Y, Imamoto H, et al. Phase II study of intraperitoneal paclitaxel plus S-1\/oxaliplatin for gastric cancer with peritoneal metastasis: SOX+IP PTX trial. J Clin Oncol. 2016;34(15(suppl)):Abst. 4040.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1767_CR76","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","volume":"28","author":"S Saito","year":"2021","unstructured":"Saito S, Yamaguchi H, Ohzawa H, Miyato H, Kanamaru R, Kurashina K, et al. Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol. 2021;28(7):3863\u201370.","journal-title":"Ann Surg Oncol"},{"key":"1767_CR77","doi-asserted-by":"crossref","unstructured":"Shi M, Yang Z, Lu S, Liu W, Ni Z, Yao X, Hua Z, Feng R, Zheng Y, Wang Z, Sah BK, Chen M, Zhu Z, He C, Li C, Zhang J, Yan C, Yan M, Zhu Z. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases. BMC cancer. 2021;21(1):1344.","DOI":"10.1186\/s12885-021-09027-5"},{"issue":"6","key":"1767_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109603","volume":"51","author":"WJ Seo","year":"2025","unstructured":"Seo WJ, Kim DW, Lee CM, Park JY, Jang YJ, Park JM, et al. Intraperitoneal paclitaxel with systemic S-1 plus oxaliplatin for advanced or recurrent gastric cancer with peritoneal metastasis: a single-arm, multicenter Phase II clinical trial. Eur J Surg Oncol. 2025;51(6):109603.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"1767_CR79","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1002\/cam4.5277","volume":"12","author":"L Tu","year":"2023","unstructured":"Tu L, Zhang W, Ni L, Xu Z, Yang K, Gou H, et al. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: a Phase II single-arm clinical trial. Cancer Med. 2023;12(4):4161\u20139.","journal-title":"Cancer Med"},{"issue":"4","key":"1767_CR80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/ajco.13659","volume":"18","author":"S Vatandoust","year":"2022","unstructured":"Vatandoust S, Bright T, Roy AC, Abbas MN, Watson DI, Gan S, et al. Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study). Asia Pac J Clin Oncol. 2022;18(4):404\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"1767_CR81","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","volume":"29","author":"SH Kang","year":"2022","unstructured":"Kang SH, Min SH, Kim JW, Lee E, Park SW, Lee S, et al. Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2022;29(8):5084\u201391.","journal-title":"Ann Surg Oncol"},{"key":"1767_CR82","doi-asserted-by":"crossref","unstructured":"Badgwell B, Ikoma N, Blum M, Wang X, Estrella J, Liu X, Kawedia J, Li J, Mansfield P, Ajani J. Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology. Cancer. 2025;131(1):e35566.","DOI":"10.1002\/cncr.35566"},{"key":"1767_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.850242","volume":"12","author":"S Zhao","year":"2022","unstructured":"Zhao S, Su L, Chen Y, Li X, Lin P, Chen W, et al. Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer. Front Oncol. 2022;12:850242.","journal-title":"Front Oncol"},{"issue":"3","key":"1767_CR84","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1245\/s10434-022-12877-3","volume":"30","author":"DKA Chia","year":"2023","unstructured":"Chia DKA, Sundar R, Kim G, Ang JJ, Shabbir A, So JBY, et al. Outcomes of a Phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2023;30(3):1889\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1767_CR85","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1245\/s10434-023-14240-6","volume":"31","author":"D Kobayashi","year":"2024","unstructured":"Kobayashi D, Kodera Y, Fukushima R, Morita M, Fushida S, Yamashita N, et al. Phase II study of intraperitoneal administration of paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2024;31(2):735\u201343.","journal-title":"Ann Surg Oncol"},{"key":"1767_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.905922","volume":"12","author":"ZY Yang","year":"2022","unstructured":"Yang ZY, Yuan F, Lu S, Xu W, Wu JW, Xi WQ, et al. Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis: a prospective Phase II study. Front Oncol. 2022;12:905922.","journal-title":"Front Oncol"},{"key":"1767_CR87","doi-asserted-by":"crossref","unstructured":"Yan C, Yang Z, Shi Z, Lu S, Shi M, Nie M, Chen J, Wu D, Mou Y, Xu Y, Wang Y, Liu X, Cao H, Gu J, Yu J, Liu K, Liu X, Zhang J, Yin K, Zhu Z. Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial. JAMA Oncol. May 21 2026.","DOI":"10.1001\/jamaoncol.2026.1347"},{"key":"1767_CR88","doi-asserted-by":"crossref","unstructured":"Yuan H, Lu S, Shi M, Yang Z, Liu W, Ni Z, et al. Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis. Future Oncol. 2023;19(38):2517\u201323.","DOI":"10.2217\/fon-2022-0738"},{"key":"1767_CR89","doi-asserted-by":"crossref","unstructured":"Senthil M, Dayyani F. Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial. BMC cancer. 2023;23(1):209.","DOI":"10.1186\/s12885-023-10680-1"},{"key":"1767_CR90","doi-asserted-by":"crossref","unstructured":"Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y, Fujimura T, Society for Study of Peritoneal Carcinomatosis in Gastric C. Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71(5):1265\u20131272.","DOI":"10.1007\/s00280-013-2122-0"},{"key":"1767_CR91","doi-asserted-by":"crossref","unstructured":"Fukushima R, Ishigami H, Miwa H, Imano M, Kobayashi D, Tsuji Y, Hidemira A, Kushumoto T, Omori T, Yabusaki H, Ohashi N, Ota M, Yamaguchi H, Kitayama J. Phase II study of intraperitoneal docetaxel plus capecitabine\/cisplatin for gastric cancer with peritoneal metastasis: XP+IP DOC trial. J Clin Oncol. 2017;35(15(suppl)):Abst.4039.","DOI":"10.1200\/JCO.2017.35.15_suppl.4039"},{"key":"1767_CR92","doi-asserted-by":"crossref","unstructured":"Cho H, Ryu MH, Kim KP, Ryoo BY, Park SR, Kim BS, et al. Phase I\/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis. Gastric Cancer. 2017;20(6):970\u20137.","DOI":"10.1007\/s10120-017-0710-0"},{"key":"1767_CR93","doi-asserted-by":"crossref","unstructured":"Bin Y, Lan D, Bao W, Yang H, Zhou S, Huang F, Wang M, Peng Z. SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation. Trials. 2022;23(1):211.","DOI":"10.1186\/s13063-022-06143-w"},{"key":"1767_CR94","doi-asserted-by":"crossref","unstructured":"Yamaguchi H, Satoh Y, Ishigami H, Kurihara M, Yatomi Y, Kitayama J. Peritoneal lavage CEA mRNA levels predict conversion gastrectomy outcomes after induction chemotherapy with intraperitoneal paclitaxel in gastric cancer patients with peritoneal metastasis. Ann Surg Oncol. 2017;24(11):3345\u201352.","DOI":"10.1245\/s10434-017-5997-x"},{"key":"1767_CR95","doi-asserted-by":"crossref","unstructured":"Emoto S, Ishigami H, Hidemura A, Yamaguchi H, Yamashita H, Kitayama J, Watanabe T. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol. 2012;42(11):1013-1019.","DOI":"10.1093\/jjco\/hys129"},{"key":"1767_CR96","doi-asserted-by":"crossref","unstructured":"Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW. Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg. Mar 2012;99(3):397-403.","DOI":"10.1002\/bjs.7812"},{"key":"1767_CR97","doi-asserted-by":"crossref","unstructured":"Kodera Y, Nakanishi H, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T, Kito T, Tatematsu M. Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer. Aug 21 1998;79(4):429-433.","DOI":"10.1002\/(SICI)1097-0215(19980821)79:4<429::AID-IJC20>3.0.CO;2-Z"},{"key":"1767_CR98","doi-asserted-by":"crossref","unstructured":"Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, Tashiro K, Yamada T, Kinoshita T, Hata H, Kawachi Y, Kawabata R, Tsuji T, Hihara J, Sakamoto T, Fukagawa T, Katai H, Higuchi K, Boku N. Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study. Ann Surg Oncol. Jan 2020;27(1):284-292.","DOI":"10.1245\/s10434-019-07697-x"},{"key":"1767_CR99","doi-asserted-by":"crossref","unstructured":"Aizawa M, Ishigami H, Yabusaki H, Nashimoto A, Imamoto H, Imano M, Yamashita H, Kishi K, Kodera Y, Uenosono Y, Fujiwara K, Hidemura A, Tamura S, Fukushima R, Yamaguchi H, Kitayama J. Phase II study of intraperitoneal paclitaxel plus S-1\/paclitaxel for gastric cancer with positive peritoneal cytology: CY-PHOENIX trial. Journal of Clinical Oncology. 2017;35(4(Suppl)):96(Abst).","DOI":"10.1200\/JCO.2017.35.4_suppl.96"},{"key":"1767_CR100","doi-asserted-by":"crossref","unstructured":"Ding P, Yang P, Tian Y, Guo H, Liu Y, Zhang Z, Zheng T, Tan B, Zhang Z, Wang D, Li Y, Zhao Q. Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study. J Gastrointest Oncol. Aug 2021;12(4):1416-1427.","DOI":"10.21037\/jgo-21-375"},{"key":"1767_CR101","doi-asserted-by":"crossref","unstructured":"Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, Kinoshita T, Kobayashi O, Arai K, Gastric Cancer Surgical Study Group in the Japan Clinical Oncology G. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer. Aug 2011;14(3):212-218.","DOI":"10.1007\/s10120-011-0027-3"},{"key":"1767_CR102","doi-asserted-by":"crossref","unstructured":"Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y, Macdonald JS. A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel\/oral fluoropyrimidine; and UFT versus S1 for T3\/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial. Jpn J Clin Oncol. Nov 2005;35(11):672-675.","DOI":"10.1093\/jjco\/hyi179"},{"key":"1767_CR103","doi-asserted-by":"crossref","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Emoto S, Watanabe T. Intraperitoneal Paclitaxel is useful as adjuvant chemotherapy for advanced gastric cancer with serosal exposure. Case Rep Oncol. Jan 2014;7(1):58-64.","DOI":"10.1159\/000358379"},{"key":"1767_CR104","doi-asserted-by":"crossref","unstructured":"Ishigami H, Tsuji Y, Shinohara H, Kodera Y, Kanda M, Yabusaki H, Ito S, Imano M, Yamashita H, Hidemura A, Yamaguchi H, Fukagawa T, Oba K, Kitayama J, Seto Y. Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial. J Clin Med. Nov 30 2021;10(23).","DOI":"10.3390\/jcm10235666"},{"key":"1767_CR105","doi-asserted-by":"crossref","unstructured":"Osumi H, Takahari D, Chin K, Ogura M, Ichimura T, Wakatsuki T, Suzuki T, Ota Y, Nakayama I, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. Onco Targets Ther. 2018;11:8301-8307.","DOI":"10.2147\/OTT.S184665"},{"key":"1767_CR106","doi-asserted-by":"crossref","unstructured":"Nakajima TE, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H, Nishina T, Sakamoto T, Shitara K, Shinozaki K, Katayama H, Nakamura S, Muro K, Terashima M. Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G). Gastric Cancer. Jul 2020;23(4):677-688.","DOI":"10.1007\/s10120-020-01043-x"},{"key":"1767_CR107","doi-asserted-by":"crossref","unstructured":"Arai H, Inoue E, Yamaguchi K, Boku N, Hara H, Nishina T, Tsuda M, Shitara K, Shinozaki K, Nakamura S, Hyodo I, Muro K, Sasako M, Terashima M, Nakajima TE. Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108\/WJOG7312G. Cancer Med. Nov 2021;10(21):7673-7682.","DOI":"10.1002\/cam4.4303"},{"key":"1767_CR108","doi-asserted-by":"crossref","unstructured":"Ito T, Hanafusa N, Iwase S, Noiri E, Nangaku M, Nakagawa K, Miyagawa K. Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites. Int J Clin Oncol. Jun 2015;20(3):623-628.","DOI":"10.1007\/s10147-014-0750-y"},{"key":"1767_CR109","doi-asserted-by":"crossref","unstructured":"Matsusaki K, Orihashi K. Feasibility, efficacy, and safety of cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites. Artif Organs. Oct 2020;44(10):1090-1097.","DOI":"10.1111\/aor.13691"},{"key":"1767_CR110","doi-asserted-by":"crossref","unstructured":"Nagata Y, Kato K, Miyamoto T, Hirano H, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Matsushita H, Nagashima K, Saruta M, Boku N. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy. Support Care Cancer. Dec 2020;28(12):5861-5869.","DOI":"10.1007\/s00520-020-05401-4"},{"key":"1767_CR111","doi-asserted-by":"crossref","unstructured":"Yamaguchi H, Kitayama J, Emoto S, Ishigami H, Ito T, Hanafusa N, Watanabe T. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. Eur J Surg Oncol. Jul 2015;41(7):875-880.","DOI":"10.1016\/j.ejso.2015.04.013"},{"key":"1767_CR112","doi-asserted-by":"crossref","unstructured":"Kang SH, Kim JW, Lee E, Yoo M, Jeon D, Park W, Kang M, Oh HJ, Min SH, Park YS, Kim TH, Lee YJ, Kim JW, Ahn SH, Suh YS, Lee KW, Lee HS, Kim HH. Intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, oxaliplatin (FOLFOX) and nivolumab for gastric cancer with peritoneal metastasis: results from the IPLUS Phase II study. Gastric Cancer. Apr 19 2026.","DOI":"10.1007\/s10120-026-01741-y"},{"key":"1767_CR113","doi-asserted-by":"crossref","unstructured":"Gallanis AF, Perati SR, Canady SN, Epstein M, Moore N, Satterwhite AA, Mallory Y, Ahn D, Bowden C, Figueiroa S, Lee JJ, de Souza A, Shin S, Ahmed J, Sullivan MA, Joyce SR, Hernandez JM, Chen A, Alewine CC, Davis JL, Blakely AM. Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials. Ann Surg Oncol. May 2026;33(5):4679-4689.","DOI":"10.1245\/s10434-025-18967-2"},{"key":"1767_CR114","doi-asserted-by":"crossref","unstructured":"Nowacki M, Peterson M, Kloskowski T, McCabe E, Guiral DC, Polom K, Pietkun K, Zegarska B, Pokrywczynska M, Drewa T, Roviello F, Medina EA, Habib SL, Zegarski W. Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. Oncotarget. Sep 29 2017;8(44):78208-78224.","DOI":"10.18632\/oncotarget.20596"},{"key":"1767_CR115","doi-asserted-by":"crossref","unstructured":"Perello-Trias MT, Serrano-Munoz AJ, Rodriguez-Fernandez A, Segura-Sampedro JJ, Ramis JM, Monjo M. Intraperitoneal drug delivery systems for peritoneal carcinomatosis: Bridging the gap between research and clinical implementation. J Control Release. Sep 2024;373:70-92.","DOI":"10.1016\/j.jconrel.2024.07.017"},{"key":"1767_CR116","doi-asserted-by":"crossref","unstructured":"Li C, Newman RA, Wu QP, Ke S, Chen W, Hutto T, Kan Z, Brannan MD, Charnsangavej C, Wallace S. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol. 2000;46(5):416-422.","DOI":"10.1007\/s002800000168"},{"key":"1767_CR117","doi-asserted-by":"crossref","unstructured":"Yamada J, Kitayama J, Tsuno NH, Yamashita H, Miyato H, Soma D, Otani K, Kamei T, Ishigami H, Hidemura A, Kaisaki S, Takahashi K, Nagawa H. Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer. Cancer Lett. Dec 18 2008;272(2):307-315.","DOI":"10.1016\/j.canlet.2008.07.024"},{"key":"1767_CR118","doi-asserted-by":"crossref","unstructured":"Emoto S, Yamaguchi H, Kishikawa J, Yamashita H, Ishigami H, Kitayama J. Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. Cancer Sci. Jul 2012;103(7):1304-1310.","DOI":"10.1111\/j.1349-7006.2012.02274.x"},{"key":"1767_CR119","doi-asserted-by":"crossref","unstructured":"Bajaj G, Kim MR, Mohammed SI, Yeo Y. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release. Mar 28 2012;158(3):386-392.","DOI":"10.1016\/j.jconrel.2011.12.001"},{"key":"1767_CR120","unstructured":"Shen YA, Li WH, Chen PH, He CL, Chang YH, Chuang CM. Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol((R))-resistant ovarian cancer. Am J Transl Res. 2015;7(5):841-855."},{"key":"1767_CR121","doi-asserted-by":"crossref","unstructured":"De Clercq K, Xie F, De Wever O, Descamps B, Hoorens A, Vermeulen A, Ceelen W, Vervaet C. Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer. Sci Rep. Oct 16 2019;9(1):14881.","DOI":"10.1038\/s41598-019-51419-y"},{"key":"1767_CR122","doi-asserted-by":"crossref","unstructured":"Simon-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju VR, Sugahara KN, Tammik O, Ruoslahti E, Battaglia G, Teesalu T. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. Biomaterials. Oct 2016;104:247-257.","DOI":"10.1016\/j.biomaterials.2016.07.023"},{"key":"1767_CR123","doi-asserted-by":"crossref","unstructured":"Simon-Gracia L, Hunt H, Scodeller PD, Gaitzsch J, Braun GB, Willmore AM, Ruoslahti E, Battaglia G, Teesalu T. Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy. Mol Cancer Ther. Apr 2016;15(4):670-679.","DOI":"10.1158\/1535-7163.MCT-15-0713-T"},{"key":"1767_CR124","doi-asserted-by":"crossref","unstructured":"Fan R, Tong A, Li X, Gao X, Mei L, Zhou L, Zhang X, You C, Guo G. Enhanced antitumor effects by docetaxel\/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer. Int J Nanomedicine. 2015;10:7291-7305.","DOI":"10.2147\/IJN.S89066"},{"key":"1767_CR125","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang S, Duan X, Xu X, Gao Y, Zhou J, Xu X, Li J. mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis. Front Pharmacol. 2022;13:861938.","DOI":"10.3389\/fphar.2022.861938"},{"key":"1767_CR126","doi-asserted-by":"crossref","unstructured":"Liu M, Silva-Sanchez A, Randall TD, Meza-Perez S. Specialized immune responses in the peritoneal cavity and omentum. J Leukoc Biol. Apr 2021;109(4):717-729.","DOI":"10.1002\/JLB.5MIR0720-271RR"},{"key":"1767_CR127","doi-asserted-by":"crossref","unstructured":"Takahashi K, Kurashina K, Yamaguchi H, Kanamaru R, Ohzawa H, Miyato H, Saito S, Hosoya Y, Lefor AK, Sata N, Kitayama J. Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer. Front Immunol. 2022;13:969468.","DOI":"10.3389\/fimmu.2022.969468"},{"key":"1767_CR128","doi-asserted-by":"crossref","unstructured":"Matsumiya M, Sonoda H, Yamashita H, Kurashina K, Takahashi K, Ohzawa H, Miyato H, Matsumoto S, Saito S, Hosoya Y, Sata N, Kitayama J, Yamaguchi H. Intraperitoneal Paclitaxel-Induced Eosinophil Recruitment as a Potential Mediator of Tumor Response in Peritoneal Metastases from Gastric Cancer. Ann Surg Oncol. Jan 29 2026.","DOI":"10.1245\/s10434-025-19075-x"},{"key":"1767_CR129","doi-asserted-by":"crossref","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. Feb 2017;17(2):97-111.","DOI":"10.1038\/nri.2016.107"},{"key":"1767_CR130","doi-asserted-by":"crossref","unstructured":"Zhu Z, Kitayama J, Kim HH, So JB, Cao H, Chen L, Cheng X, Hu J, Imano M, Ishigami H, Jee YS, Kim JH, Kodera Y, Liang H, Liu X, Lu S, Mou Y, Nie M, Seo WJ, Wang Y, Wu D, Xu Z, Yamaguchi H, Yan C, Yang Z, Yin K, Yonemura Y, Yong WP, Yu J, Zhang J, Asian Gastric Cancer NTCG. Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis. Gastric Cancer. Sep 2025;28(5):731-748.","DOI":"10.1007\/s10120-025-01631-9"},{"key":"1767_CR131","doi-asserted-by":"crossref","unstructured":"Boshier PR, Chia DKA, Thrumurthy SG, Teh JL, Wobith M, Bencivenga M, Filippini F, Dumitra TC, Burch M, Kim HI, Kobitzsch B, Kodach LL, Quik JSE, Long VD, de Neijs MJ, van der Sluis PC, Leon-Takahashi AM, Woo Y, Chevallay M, Framarini M, Morgagni P, Frejlich E, Grabsch HI, Markar SR, Marrelli D, Park DJ, Sundar R, Xu Z, Linn KK, Yang HK, Kitayama J, Zhu Z, Rha SY, Wijnhoven B, Yamashita H, Yong WP, de la Fouchardiere C, Nilsson M, Ishigami H, Van Sandick JW, Lordick F, Badgwell BD, So JBY. Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements. Br J Surg. Apr 9 2026;113(4).","DOI":"10.1093\/bjs\/znag027"},{"key":"1767_CR132","doi-asserted-by":"crossref","unstructured":"Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. Mar 2018;68(2):153-165.","DOI":"10.3322\/caac.21443"},{"key":"1767_CR133","doi-asserted-by":"crossref","unstructured":"Itani Y, Obama K, Fujimori M, Saito J, Uchitomi Y. Cancer treatment-related financial toxicity in Japan: a scoping review. Front Psychol. 2023;14:1205016.","DOI":"10.3389\/fpsyg.2023.1205016"},{"key":"1767_CR134","unstructured":"Connaughton R. Rising Sun and Tumbling Bear- Russia's war with Japan. Cassell Militarr Paperbacks; 2002."}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01767-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01767-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01767-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:02:30Z","timestamp":1787900550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01767-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1767"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01767-2","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}